MXCT sentiment intelligence

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

MaxCyte, Inc. announced that it will release its second quarter 2026 financial results after the U.S. market closes on Wednesday, August 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors are encouraged to register onli

Tone

Neutral 50/100

Event

Earnings

Published

16 Jul 2026 04:07

Source

The Manila Times

MaxCyte to report Q2 2026 financial results on August 12

MaxCyte, Inc. is scheduled to release its second-quarter 2026 financial results after the U.S. market close on Wednesday, August 12, 2026. This will be followed by a conference call hosted by company management at 4:30 p.m. Eastern Time. Investors are required to register online

Tone

Neutral 50/100

Event

Earnings

Published

15 Jul 2026 21:39

Source

scanx.trade

MaxCyte will discuss second-quarter results on Aug. 12

MaxCyte (NASDAQ: MXCT) announced it will release its second quarter 2026 financial results after the U.S. market closes on Wednesday, August 12, 2026. Following the release, company management will host an earnings conference call at 4:30 p.m. Eastern Time, which investors can ac

Tone

Neutral 50/100

Event

Earnings

Published

15 Jul 2026 20:05

Source

Stock Titan

Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q1 Earnings: Integer Holdings (NYSE:ITGR)

Tone

Neutral 50/100

Event

Earnings

Published

14 Jul 2026 18:07

Source

Market source

Enterprise value to revenue forward of MaxCyte, Inc. – DUS:MYE0

The article displays the enterprise value to revenue forward for MaxCyte, Inc. (DUS:MYE0) on the Dusseldorf Stock Exchange. It provides a financial overview of the company, indicating the market was closed with no trades recorded at the time of the report. The content appears to

Tone

Neutral 50/100

Event

Earnings

Published

12 Jul 2026 13:39

Source

TradingView

Price to sales forward of MaxCyte, Inc. – DUS:MYE0

This article provides the "Price to sales forward" financial metric for MaxCyte, Inc. (DUS:MYE0) on the Dusseldorf Stock Exchange, as presented on the TradingView platform. It acknowledges that the market is currently closed with no trades. The content is primarily a data point w

Tone

Neutral 50/100

Event

Market update

Published

12 Jul 2026 00:10

Source

TradingView

MaxCyte(MXCT) Stock Options Chain | Quotes & News

This article provides details on the stock options chain for MaxCyte (MXCT). It also indicates that quotes and news related to MaxCyte are available.

Tone

Neutral 50/100

Event

Market update

Published

09 Jul 2026 08:11

Source

Moomoo

Price to earnings forward of MaxCyte, Inc. – DUS:MYE0

This article displays the "Price to earnings forward" metric for MaxCyte, Inc. (DUS:MYE0) on TradingView. It appears to be a financial data point presented without further commentary or analysis, indicating market performance data. The content primarily consists of navigation and

Tone

Neutral 50/100

Event

Earnings

Published

09 Jul 2026 06:41

Source

TradingView

Enterprise value to EBITDA forward of MaxCyte, Inc. – NASDAQ:MXCT

This article provides the enterprise value to EBITDA forward for MaxCyte, Inc. (NASDAQ: MXCT). It appears to be a financial data snippet from TradingView, indicating the value and any changes for the specified financial metric. The content itself seems to be a display of this sin

Tone

Neutral 50/100

Event

Market update

Published

04 Jul 2026 11:09

Source

TradingView

Price to book forward of MaxCyte, Inc. – NASDAQ:MXCT

This article provides a brief snapshot of the "Price to book forward" metric for MaxCyte, Inc. (NASDAQ:MXCT) on TradingView. It shows the period, value, and change percentages for this financial indicator. The content is concise and focused solely on this specific financial data

Tone

Neutral 50/100

Event

Market update

Published

29 Jun 2026 15:09

Source

TradingView

Price to sales forward of MaxCyte, Inc. – LS:A2AGVE

This article provides access to the "Price to sales forward" financial metric for MaxCyte, Inc. (A2AGVE) on the TradingView platform. It highlights that market data is provided by ICE Data Services and FactSet, and SEC filings by Quartr. The content mainly consists of navigation

Tone

Neutral 50/100

Event

Market update

Published

29 Jun 2026 08:40

Source

TradingView

MXCT Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for MaxCyte, Inc. (MXCT) stock, based on analyst ratings and current market data. It includes information on the company's past performance, stock volatility, market capitalization, earnings, revenue, and future outlook, as well a

Tone

Neutral 50/100

Event

Earnings

Published

26 Jun 2026 02:09

Source

TradingView

MYE0 Forecast — Price Target — Prediction for 2027

This article provides a forecast for MaxCyte, Inc. (MYE0) stock, including analyst price targets, past financial performance, and key company metrics. It details the stock's highest and lowest recorded prices, upcoming earnings reports, and financial statistics such as revenue, n

Tone

Neutral 50/100

Event

Earnings

Published

26 Jun 2026 01:09

Source

TradingView

MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT)

This article provides an overview of MaxCyte, Inc. (NASDAQ:MXCT) stock, including its current price, performance, and analyst forecasts. It covers financial data, market capitalization, earnings reports, and technical analysis, noting that MXCT's stock has shown recent gains but

Tone

Neutral 50/100

Event

Earnings

Published

25 Jun 2026 17:09

Source

TradingView

MaxCyte (MXCT) grants RSUs and stock options to director

MaxCyte (MXCT) director John Joseph Johnston was granted 30,421 restricted stock units and stock options for 49,579 shares as part of his annual non-employee director compensation. The RSUs will vest on June 17, 2027, contingent on his continued service, and the stock options hav

Tone

Neutral 50/100

Event

Market update

Published

23 Jun 2026 13:09

Source

Stock Titan

MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant

MAXCYTE director Cynthia Collins was granted 30,421 restricted stock units and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. These equity awards, made on June 17, 2026, are part of the company's Equity Grant Policy for non-employee di

Tone

Neutral 50/100

Event

Market update

Published

23 Jun 2026 13:09

Source

Stock Titan

Form 4 MaxCyte Inc For: 22 June By Investing.com

This article from Investing.com is a regulatory filing update, specifically a Form 4 for MaxCyte Inc, dated June 22. It primarily serves as a notice of the filing without providing further details on the content of the form itself. The content primarily consists of market data an

Tone

Neutral 50/100

Event

Regulatory and legal

Published

22 Jun 2026 22:28

Source

Investing.com South Africa

MaxCyte (MXCT) director receives RSUs and options in annual equity grant

MaxCyte Inc. director Stanley C. Erck received an annual equity grant comprising 30,421 restricted stock units (RSUs) and an option to purchase 49,579 shares at $1.13 per share. The RSUs will vest on June 17, 2027, contingent on his continued service. Following this grant, Erck's

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 20:40

Source

Stock Titan

MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award

MAXCYTE (NASDAQ: MXCT) director Douglas Richard was granted 30,421 Restricted Stock Units (RSUs) and 49,579 stock options with an exercise price of $1.13 per share. These grants are part of the company's annual equity award policy for non-employee directors, with the RSUs vesting

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 20:39

Source

Stock Titan

MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant

MaxCyte (MXCT) director Brooke William W was granted 30,421 restricted stock units (RSUs) and stock options for 49,579 shares of Common Stock at an exercise price of $1.13 per share. The RSUs vest on June 17, 2027, contingent on his continuous service, and the stock options expir

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 20:39

Source

Stock Titan

MaxCyte (MXCT) director receives RSU and stock option grant

MaxCyte (MXCT) director Yasir B. Al-Wakeel was granted 30,421 restricted stock units (RSUs) and stock options for 49,579 shares at an exercise price of $1.13 per share. These equity awards are part of his annual non-employee director compensation package, with the shares vesting

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 20:39

Source

Stock Titan

MaxCyte (MXCT) director awarded RSUs and stock options in annual grant

MaxCyte, Inc. director Rekha Hemrajani received an annual equity grant comprising 30,421 restricted stock units (RSUs) and 49,579 stock options with a strike price of $1.13, expiring in 2036. These awards, part of the non-employee director policy, vest on June 17, 2027, contingen

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 20:39

Source

Stock Titan

MaxCyte (MXCT) director Patrick Balthrop receives RSU and stock option grants

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 07:00

Source

Stock Titan

MaxCyte Stock - chart levels and volatility on a quiet news day

MaxCyte stock traded on Nasdaq without new corporate headlines, leading analysts to focus on its chart performance, volatility, and key moving averages. The company, which develops cell-engineering technologies for biopharma partners, is in a period of consolidation. Investors ar

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 16:40

Source

AD HOC NEWS

MaxCyte shareholders elect directors and approve auditor at annual meeting

MaxCyte, Inc. announced the results of its 2026 annual meeting, where shareholders elected three Class II directors—Patrick Balthrop, Cynthia Collins, and Stanley Erck—and ratified CohnReznick LLP as its independent auditor for the fiscal year ending December 31, 2026. Despite th

Tone

Neutral 50/100

Event

Earnings

Published

18 Jun 2026 11:40

Source

Investing.com